SEC FORM 4

SEC FORM 4SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/07/2026		S⁽¹⁾		11,217	D	$67.495⁽²⁾	584,469	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/07/2026		S⁽¹⁾		8,333	D	$68.3775⁽⁴⁾	576,136	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/07/2026		S⁽¹⁾		450	D	$69.0911⁽⁵⁾	575,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/07/2026		S⁽¹⁾		11,217	D	$67.4949⁽²⁾	4,387,230	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/07/2026		S⁽¹⁾		8,334	D	$68.3775⁽⁴⁾	4,378,896	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/07/2026		S⁽¹⁾		449	D	$69.0911⁽⁵⁾	4,378,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/08/2026		S⁽¹⁾		13,973	D	$66.6505⁽⁶⁾	561,713	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/08/2026		S⁽¹⁾		5,077	D	$67.3455⁽⁷⁾	556,636	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/08/2026		S⁽¹⁾		950	D	$68.3477⁽⁸⁾	555,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/08/2026		S⁽¹⁾		13,974	D	$66.6505⁽⁶⁾	4,364,473	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/08/2026		S⁽¹⁾		5,076	D	$67.3455⁽⁷⁾	4,359,397	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock	05/08/2026		S⁽¹⁾		950	D	$68.3477⁽⁸⁾	4,358,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽³⁾
Common Stock								234,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $67.02 to $68.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. Represents the weighted average sale price of the shares sold from $68.02 to $69.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. Represents the weighted average sale price of the shares sold from $69.02 to $69.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

6. Represents the weighted average sale price of the shares sold from $66.10 to $67.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

7. Represents the weighted average sale price of the shares sold from $67.10 to $68.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

8. Represents the weighted average sale price of the shares sold from $68.17 to $68.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Chief Executive Officer Kumar Neil sold $5,392,243 worth of shares (80,000 units at $67.40) as part of a pre-agreed trading plan (SEC Form 4)